Companies: 10,795·Total market cap: $144.5T
MorphoSys AG

MorphoSys AG

MORNASDAQHealthcare
$18.96
+$0.45(+2.43%)
Market Cap$2.9B
P/E Ratio—
52W High$19.5
52W Low$4.185
Cash on HandFinancialsRevenue

MorphoSys AG (MOR) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

MOR · cash on hand · updated Dec 31, 2023

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$682.8M▼ -24.7% vs prior year
FY · as of Dec 31, 2023 · Reported in EUR
Cash & Cash Equiv. (CCE)
$158.5M
cashAndCashEquivalents
Short-Term Investments
$524.3M
shortTermInvestments
YoY Change vs Prior Year
-24.7%
vs prior fiscal year
Latest Quarter
$630.8M
Q1 2024
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in EUR

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2023

Net cash vs debt

Cash & ST Investments$682.8MCash on Hand
Total Debt$635.9MTotal Debt
Net Cash / Net Debt+$46.8MNet Cash Position
Cash vs Debt Ratio
Cash 52%Debt 48%

MorphoSys AG has a net cash position of $46.8M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$682.8M − $635.9M = +$46.8M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
MOR annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2023Latest$682.8M-24.7%
Dec 31, 2022$907.2M-8.7%
Dec 31, 2021$993.7M-8.9%
Dec 31, 2020$1.09B+300.1%
Dec 31, 2019$272.5M-24.1%
MOR cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
MorphoSys AG
MorphoSys AGYOU
MOR
$682.8M23.9%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

MorphoSys AG (MOR) cash on hand as of December 31, 2023 is $682.8M, comprising $158.5M in cash and cash equivalents (CCE) plus $524.3M in short-term investments — reported as MorphoSys AG cash and short-term investments on the balance sheet (10-K filing). Also referred to as MorphoSys AG cash reserves or cash position.

MorphoSys AG annual cash on hand history shows decreased -24.7% in 2023: decreased -24.7% in 2023. MorphoSys AG cash reserves in 2023 reflect the company's capital allocation strategy.

MorphoSys AG carries total debt of $635.9M against cash of $682.8M, resulting in a net cash position of +$46.8M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

MOR cash on hand · 5 questions

As of December 31, 2023, MorphoSys AG (MOR) has $682,755,659 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $158,500,000 in cash and cash equivalents (CCE) plus $524,255,659 in short-term investments. Latest quarter (March 31, 2024): $630,772,622. Data sourced from the annual 10-K filing via FMP.

MOR cash on handMOR cash reservesMOR cash 2023how much cash does MOR have

▸ Source: FMP /balance-sheet-statement · US GAAP · MorphoSys AG · MorphoSys AG SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2023